SCHEMBL614704

SCHEMBL614704

Cc1c2ccnc(Cl)c2cc2c1[nH]c1ccc(O)cc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 6/20 0.53
PDGFRA P16234 2/20 0.53
FGFR3 P22607 2/20 0.53
NQO2 P16083 1/20 0.47
HTR2C P28335 1/20 0.44
HTR2B P41595 1/20 0.44
HTR5A P47898 1/20 0.44
BCHE P06276 2/20 0.43
ACHE P22303 1/20 0.43
DYRK1A Q13627 1/20 0.39
NR1I2 O75469 1/20 0.37
KDM4E B2RXH2 1/20 0.37
GABRP O00591 1/20 0.37
GABRD O14764 1/20 0.37
GABRA1 P14867 1/20 0.37
GABRB1 P18505 1/20 0.37
GABRG2 P18507 1/20 0.37
GABRB3 P28472 1/20 0.37
GABRA5 P31644 1/20 0.37
GABRA3 P34903 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL614041 0.82 KIT (0.58) KITNQO2HTR2CHTR2BHTR5A
SCHEMBL2311050 0.80 KIT (0.49) KITPDGFRAFGFR3NQO2ACHE
SCHEMBL10022320 0.78 KIT (0.46) KITPDGFRAFGFR3NQO2BCHE
SCHEMBL12387156 0.78 KIT (0.47) KITPDGFRAFGFR3NQO2HTR2C
SCHEMBL614042 0.78 MAOA (0.55) KITNQO2BCHEDYRK1AKDM4E
SCHEMBL11096433 0.77 MAOA (0.55) KITNQO2HTR2CBCHEACHE
SCHEMBL6456554 0.76 MAOA (0.61) KITPDGFRAFGFR3HTR2CHTR2B
SCHEMBL24276808 0.75 KIT (0.64) KITPDGFRAFGFR3HTR2CHTR2B
SCHEMBL5361349 0.75 KIT (0.51) KITPDGFRAFGFR3NQO2HTR2C
Dimethylamine SCHEMBL8548190 0.74 KIT (0.46) KITPDGFRAFGFR3NQO2HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8604048-B2 Pyridocarbazole type compounds and applications thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-12-10 US disclosed
US-20120041017-A1 PYRIDOCARBAZOLE TYPE COMPOUNDS AND APPLICATIONS THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2012-02-16 US disclosed
US-20120041017-A1 PYRIDOCARBAZOLE TYPE COMPOUNDS AND APPLICATIONS THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2012-02-16 US disclosed
US-20120041017-A1 PYRIDOCARBAZOLE TYPE COMPOUNDS AND APPLICATIONS THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2012-02-16 US disclosed
WO-2010095042-A2 PYRIDOCARBAZOLE TYPE COMPOUNDS AND APPLICATIONS THEREOF CENTRE NATONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2010-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120041017-A1 PYRIDOCARBAZOLE TYPE COMPOUNDS AND APPLICATIONS THEREOF NLN, OPA1, PYCR1 KIT 4688/4885PDGFRA 3344/4885FGFR3 3741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.